BioSpace News Archive

Maintains Strong Balance Sheet; Momentum Continues for Modified Risk Tobacco Product and Major Milestone Achieved in Hemp/Cannabis Research

Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the fourth quarter and full year ending December 31, 2019 and provided a business update. “We are working to advance our lead program, SGT-001, a gene therapy candidate for Duchenne muscular dystrophy.

IRADIMED CORPORATION (NASDAQ: IRMD) announced the appointment of Lynn Neuhardt as Vice President of Research and Development, effective March 26, 2020.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2019.

Rubius Therapeutics, Inc. today reported fourth quarter and full year 2019 financial results.

Positive data from Phase 1b preventing immune-mediated diseases.

Plans to Focus on Phase 3 Programs in Allergic Conjunctivitis, Dry Eye Disease, and Proliferative Vitreoretinopathy Expected to Extend Company’s Cash Runway Through the End of 2021 Ophthalmology Drug Development Expert James A. Gow, M.D., Named Senior Vice President of Clinical Development LEXINGTON, Mass.--( BUSINESS WIRE )-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-sta

ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that it has agreed to a product supply agreement with EyeCare Services Partners (ESP).

Phesi, a data-driven provider of premier integrated clinical development products and services, today announced that the company has filed a new patent [U.S. Serial No. 62/986,746] that enables its systems to synthesize global patient data and assess baseline patient characteristics for clinical trial protocols

Agenus Inc.today announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab [PD-1] in combination with zalifrelimab [CTLA-4]